-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
March 20, 2020 /--- Researchers at the University of Tennessee Health Science Center and colleagues at the MD Anderson Cancer Center in Houston found that some antibodies produced by SARS-CoV-2 infection are more protective than others when they are re-infected.
the study, published in the journal JCI Insight, helped to deepen understanding of the virus and the immune response associated with infection.
Michael Whitt, associate dean of the American Academy of Sciences, was the study's principal director.
Whitt and his team used assays or test procedures developed in his lab about 25 years ago to study the ebola virus's infection.
recently, they used the trial to study SARS-CoV-2 infections and the resulting immunity.
June 2017 to June 2020, the researchers analyzed samples from 134 hospitalized COVID patients and 464 healthy individuals to test for the presence of positive antibodies.
Whitt explains: "The mediator antibody is directed at the hedgehog protein, which is responsible for the binding of the virus to the host cell receptor and the entry of the virus into the cell.
, not all anti-S-protein antibodies are immune, so only anti-S-protein antibodies can prevent infection.
of the problems we have to solve is, do all patients produce a negative antibody?" The answer is clearly no.
question is, what level of antibodies can they produce for patients who produce meso-antibodies? Researchers from the Department of Microbiology, Immunology and Biochemistry, together with Dr. Whitt, are working on ways to test SARS-CoV-2 antibodies in the general population.
Maria Gomes-Solecki and her team have developed and are testing the ELISA solution.
(bioon.com) Source: Researchers advanced COVID-19 antibody knowledge Original source: Kathleen M. McAndrews et al, Heterogeneous antibodies st SARS-CoV-2 spike receptor binding domain and nucleocapsid with accounts for COVID-19 i i, JCI Insight (2020). DOI: 10.1172/jci.insight.142386.